Search

Exelixis Inc

Fechado

SetorSaúde

59.56 1.21

Visão Geral

Variação de preço das ações

24h

Atual

Mín

58.8

Máximo

60.73

Indicadores-chave

By Trading Economics

Rendimento

1.6M

212M

Vendas

18M

629M

P/E

Médio do Setor

18.565

47.946

EPS

0.82

Margem de lucro

33.729

Funcionários

1,077

EBITDA

-12M

263M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

-11.39% downside

Dividendos

By Acuity

Próximos Ganhos

3 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

742M

15B

Abertura anterior

58.35

Fecho anterior

59.56

Sentimento de Notícias

By Acuity

50%

50%

114 / 340 Ranking em Healthcare

Exelixis Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

9 de out. de 2026, 20:06 UTC

News

RBC Capital raised its price target on Exelixis Inc to $51 while maintaining a Sector Perform rating, coinciding with the stock's positive performance.

8 de out. de 2026, 20:07 UTC

Exelixis Inc's shares advanced, supported by broader market strength, maintaining an upward trajectory despite an earlier pullback from a session high.

7 de out. de 2026, 19:45 UTC

News

Exelixis Inc shares are trading higher as Truist Securities raises the price target to $54.00 from $52.00 while maintaining a Hold rating.

6 de out. de 2026, 21:01 UTC

Exelixis Inc is trading modestly lower in after-market hours, positioned around the midpoint of its one-month trading range.

5 de out. de 2026, 21:10 UTC

Exelixis Inc. is advancing in after-market trading, closing at its highest point of the day after three consecutive sessions of gains.

2 de out. de 2026, 20:00 UTC

Exelixis Inc shares are advancing, reaching a peak cumulative return and remaining well above their 20-day moving average during Friday's market session.

1 de out. de 2026, 20:07 UTC

Exelixis Inc's shares fell modestly, reflecting routine performance amid broader market conditions, and are currently near the low end of their daily range.

30 de set. de 2026, 23:20 UTC

Exelixis Inc shares are higher in after-market trading, continuing a five-day gain, supported by strong Q2 GDP growth despite mixed inflation and consumer spending signals.

29 de set. de 2026, 20:31 UTC

Exelixis Inc saw a significant decline in after-market trading, continuing a downward trend since Tuesday's close following earlier gains.

28 de set. de 2026, 19:16 UTC

Exelixis Inc is trading modestly higher, currently 2.25% above its 20-day moving average, reflecting routine activity for this time of day.

25 de set. de 2026, 23:20 UTC

Exelixis Inc is lower in after-market trading, retracing from an early gain and reflecting a decline since Friday's close.

24 de set. de 2026, 20:01 UTC

Exelixis Inc is advancing, peaking in mid-afternoon while remaining above its 20-day moving average and near the upper end of its one-month range.

23 de set. de 2026, 20:07 UTC

Exelixis Inc shares fell significantly on Wednesday, having briefly spiked earlier in the session, reflecting a lack of momentum in either direction.

22 de set. de 2026, 20:06 UTC

Exelixis Inc is gaining today, building on Monday's momentum, with the stock remaining above its 20-day moving average and near its one-month range's upper end.

21 de set. de 2026, 23:25 UTC

Exelixis Inc is trading modestly lower in after-market hours, continuing a decline seen over the past three sessions after reaching a session high.

18 de set. de 2026, 20:06 UTC

Exelixis Inc's shares fell sharply after reaching a notable peak earlier in the session, while remaining above the 20-day moving average.

16 de set. de 2026, 20:07 UTC

Exelixis Inc shares fell sharply, retracing from an early peak in cumulative return amid unusually high market volume on Wednesday.

15 de set. de 2026, 20:07 UTC

News

Exelixis Inc. shares are higher as the company expands CABOMETYX in renal cell carcinoma and neuroendocrine tumors, reflecting investor confidence amid broader market concerns.

14 de set. de 2026, 20:07 UTC

News

Exelixis shares are rising after BMO indicated the FDA's PDUFA date extension for Zanzalintinib is procedural, maintaining a $55 price target.

11 de set. de 2026, 20:01 UTC

Macro Event
Social Media
News

Exelixis shares are lower as the FDA extends the review period for zanzalintinib by three months, now set for March 3, 2027.

10 de set. de 2026, 20:07 UTC

News

Exelixis Inc shares are lower amid market reaction to the European Central Bank's interest rate hike. The stock briefly recovered earlier in the session.

9 de set. de 2026, 20:07 UTC

News

Exelixis announced a $2 million milestone payment to Adagene for preclinical progress on the XB404 program, boosting shares in Wednesday's session.

8 de set. de 2026, 19:51 UTC

News

Exelixis Inc shares are lower today, influenced by a decline in the Biotechnology sub-sector, breaking a trend of higher daily closes since Friday.

3 de set. de 2026, 20:07 UTC

Exelixis Inc is advancing during Thursday's session, maintaining upward momentum since Wednesday. No specific news was identified to explain the price movement.

2 de set. de 2026, 23:56 UTC

Exelixis Inc shares are higher in after-market trading, though no specific news was identified. The broader market reacted to weaker ADP payroll data.

1 de set. de 2026, 23:06 UTC

Exelixis Inc. shares are lower in after-market hours, with no specific news identified for the decline amid broader market concerns.

31 de ago. de 2026, 22:16 UTC

Exelixis shares are higher in after-market hours, rebounding from a slight dip earlier. This follows broader market reactions to Federal Reserve comments on inflation.

28 de ago. de 2026, 23:01 UTC

Exelixis Inc shares are lower in after-market hours, continuing a trend of declines amid rising interest rate hike expectations affecting the biotechnology sector.

27 de ago. de 2026, 20:07 UTC

Exelixis Inc shares are trading lower amid broader market declines. The cumulative return has reached a low point, with no specific news driving the movement.

26 de ago. de 2026, 23:01 UTC

Exelixis Inc's shares are higher in after-market trading, reaching a high of 0.73% above Wednesday's close and 5.12% above its 20-day moving average.

Comparação entre Pares

Variação de preço

Exelixis Inc Previsão

Preço-alvo

By TipRanks

-11.39% parte inferior

Previsão para 12 meses

Média 52.3 USD  -11.39%

Máximo 64 USD

Mínimo 41 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Exelixis Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

13 ratings

3

Comprar

9

Manter

1

Vender

Sentimento

By Acuity

114 / 340 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.